Improvement in prognosis of dilated cardiomyopathy in the elderly over the past 20 years  by Kubo, Toru et al.
Journal of Cardiology (2008) 52, 111—117
ORIGINAL ARTICLE
Improvement in prognosis of dilated
cardiomyopathy in the elderly
over the past 20 years
Toru Kubo (MD), Yoshihisa Matsumura (MD), Hiroaki Kitaoka (MD),
Makoto Okawa (MD), Takayoshi Hirota (MD), Tomoyuki Hamada (MD),
Nobuhiko Hitomi (MD), Eri Hoshikawa (MD), Kayo Hayato (MD),
Yuji Shimizu (MD), Naohito Yamasaki (MD), Toshikazu Yabe (MD),
Masanori Nishinaga (MD), Jun Takata (MD), Yoshinori Doi (MD) ∗
Department of Medicine and Geriatrics, Kochi Medical School, Oko-cho, Nankoku-shi, Kochi 783-8505,
Japan
Received 25 April 2008; received in revised form 2 June 2008; accepted 3 June 2008
Available online 17 July 2008
KEYWORDS
Cardiomyopathies;
Dilated;
Elderly;
Prognosis
Summary
Background and purpose: Although dilated cardiomyopathy (DCM) had a poor prog-
nosis in the past, recent studies have shown better survival. However, little is known
about the improvement of prognosis in the elderly. This study sought to clarify the
changes in prognosis in elderly patients with DCM over the past 20 years.
Methods and subjects: We studied 54 consecutive patients with DCM (38 men and
16 women, aged 65—83 years) who were diagnosed at over 65 years of age. The
patients were divided into two groups (group A: 12 patients diagnosed before 1990;
group B: 42 patients diagnosed after 1990) because after 1990, based on growing
evidence from large-scale, randomized clinical studies, we intentionally increased
the use of angiotensin-converting enzyme inhibitors (ACEI) and then -blockers at
our hospital.
Results: There were no signiﬁcant differences in age, gender, NYHA functional class,
and the prevalence of atrial ﬁbrillation and ventricular tachycardia between the
two groups. Left ventricular (LV) size assessed by echocardiography was larger (LV
end-diastolic diameter, 67± 5.9 versus 62± 6.6mm; p = 0.039) and LV ejection frac-
tion measured by left ventriculography was lower (ejection fraction, 24± 9 versus
35± 10%; p = 0.004) in group A. ACEI/angiotensin II type 1 receptor blockers (ARB)
(0% versus 88%) or -blockers (0% versus 52%) were more frequently used in group
B. Antiarrhythmics (class Ia or Ib) (75% versus 14%) were less often used in group B.
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The 5- and 10-year event-free survival rates for cardiac death were 75.4% and 22.0%
in group A versus 81.2% and 71.3% in group B (log-rank test, p = 0.014).
Conclusions: The prognosis of DCM patients in the elderly has signiﬁcantly improved
over the past 20 years. The advances in the pharmacologic treatment and earlier
diagnosis may have contributed to the better survival.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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other institutions. The study closed on 31 December
2006.
For survival analysis, two modes of cardiac death© 2008 Japanese Colleg
reserved.
Introduction
Dilated cardiomyopathy (DCM) is a primary myocar-
dial disease of unknown cause characterized by
unexplained left ventricular (LV) dilatation and
impaired systolic function and its clinical features
and prognosis have been extensively described
[1—6]. Although DCM had a poor prognosis in the
past, recent studies have shown better survival
in the era of advancement of heart failure man-
agement [7—9]. This improvement seems partly
due to the increasing use of angiotensin-converting
enzyme inhibitors (ACEI), angiotensin II type 1
receptor blockers (ARB) and -blockers for the
treatment of heart failure due to systolic impair-
ment [10—15].
On the other hand, heart failure itself is a grow-
ing health problem because of aging populations
and increase in the prevalence of heart failure
in the elderly [16—18]. Although heart failure is
caused by various conditions, such as ischemic,
hypertensive and valvular heart diseases, cardiomy-
opathy is also important as one of the causes of
heart failure [19]. In our rapidly aging societies, in
particular, little is known about the improvement
of prognosis in elderly patients with DCM.
The purpose of this study was to analyze changes
in the long-term prognosis in elderly patients with
DCM over the past 20 years.
Subjects and methods
Subjects
We studied 54 consecutive patients with DCM (aged
65—83 years) who were diagnosed at over 65 years
of age. All patients were evaluated at the Kochi
Medical School Hospital between 1982 and 2005.
Evaluation of patients included medical history,
clinical examination, 12-lead electrocardiography
(ECG), M-mode, 2D and Doppler echocardiography,
and cardiac catheterizatrion, including coronary
angiography and biplane left ventriculography.
Left ventricular end-diastolic diameter (LVEDD)
w
(
c
tnd end-systolic diameter (LVESD) were mea-
ured from M-mode and 2D images obtained from
arasternal long-axis views, and fractional short-
ning (%FS = (LVEDD− LVESD)/LVEDD× 100) was cal-
ulated. The diagnostic criteria were (1) a dilated
eft ventricle (LVEDD> 55mm) with fractional short-
ning (%FS) <25% and (2) exclusion of patients
ith acute myocarditis, speciﬁc heart muscle dis-
ase, general systemic disease, signiﬁcant coronary
rtery stenosis (deﬁned as diameter narrowing
f >50% in any of the major coronary arteries
r their branches), valvular disease, sensitiv-
ty/toxic reactions and a history of excessive
lcohol intake. Coronary angiography was per-
ormed in 48 patients; none had signiﬁcant coronary
rtery stenosis. Results of exercise electrocardiog-
aphy and/or thallium-201 myocardial scintigraphy
ere negative for the remaining 6 patients, who
lso showed no clinical or electrocardiographic evi-
ence of coronary artery disease.
Medications of standard therapy before 1990
onsisted of diuretic agents, digoxin therapy and
ome vasodilators. After 1990, based on grow-
ng evidence from large-scale, randomized clinical
tudies, we intentionally increased the use of ACEI
nd then -blockers at our hospital. Therefore, we
ivided the patients into two groups according to
heir date of initial diagnosis—–group A: 12 patients
iagnosed between January 1982 and December
989; group B: 42 patients diagnosed between Jan-
ary 1990 and December 2005.
ollow-up
ata regarding survival and clinical status of
atients were obtained during serial clinic visits or
y direct communication with patients and their
ardiologists for patients who were followed up atere deﬁned: (1) sudden and unexpected death
including resuscitated cardiac arrest), in which
ollapse occurred in the absence of or <1 h from
he onset of symptoms in patients who previously
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xperienced a relatively stable or uneventful clini-
al course and (2) heart failure-related death which
as in the context of progressive cardiac decom-
ensation ≥1 year before death.
ata analysis
tatistical analysis was performed using SPSS (ver-
ion 14.0) statistical software (SPSS Inc., Chicago,
L, USA). All data are expressed as mean± S.D.
range) or frequency (percentage). Differences in
ontinuous variables were assessed using Student’s
-test. Pearson’s 2 test was used for comparisons
etween non-continuous variables, and Fisher’s
xact test was used when expected frequency was
ower than 5. Survival estimates were calculated by
he Kaplan—Meier method and log-rank test. Five-
ear survival values are expressed together with
heir 95% conﬁdence intervals deﬁned as survival
1.96× SE. Statistical signiﬁcance was deﬁned by
≤ 0.05.
esults
aseline characteristics
he baseline clinical characteristics of the patients
n groups A and B are shown in Table 1. There
ere no signiﬁcant differences in age, gender,
YHA functional class, and the prevalence of atrial
brillation and ventricular tachycardia. Table 2
hows echocardiographic and cardiac catheter-
zation ﬁndings. Echocardiography showed that
VEDD and LVESD were larger in group A. LV
1
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A
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Table 1 Clinical characteristics and medical treatment
Group A (1982—
Patients (n) 12
Age (years) 69± 2
Gender: male, n (%) 10 (83%)
NYHA class, n (%)
I and II 6 (50%)
III and IV 6 (50%)
Atrial ﬁbrillation, n (%) 2 (17%)
VT, n (%) 4 (33%)
ACEI/ARB, n (%) 0 (0%)
-Blocker, n (%) 0 (0%)
Antiarrhythmics (class Ia/Ib), n (%) 6/3 (75%)
Diuretics, n (%) 11 (92%)
Digitalis, n (%) 11 (92%)
Calcium antagonists, n (%) 3 (25%)
Data shown as mean± S.D. or number (%). NYHA, New York Heart
converting enzyme inhibitors; ARB, angiotensin II type 1 receptor bthe elderly over the past 20 years 113
jection fraction (EF) measured by biplane left ven-
riculography was lower in group A, although LV
olume and pressure data were not signiﬁcantly
ifferent.
The baseline medical treatment is also shown
n Table 1. Diuretics were basically used to relieve
uid retention in both groups. There was no differ-
nce in the use of digitalis and calcium antagonists.
CEI/ARB and -blockers were more frequently
sed in group B than in group A. On the other hand,
ntiarrhythmics (class Ia or Ib) were less often used
n group B.
urvival
he follow-up periods in group A and group B
ere 4.1± 4.2 years (range: 1.0—14.5 years) and
.5± 4.4 years (range: 0.1—15.3 years), respec-
ively. In group A, all 12 patients died (cardiac
eaths in 9 patients, non-cardiac deaths in 2
atients, and unknown cause in 1 patient). In
roup B, 16 of the 42 patients died (cardiac
eaths in 8 patients, non-cardiac deaths in 4
atients, and unknown causes in 4 patients) (Fig. 1).
aplan—Meier analysis showed that survival curves
or all-cause mortality and cardiac death were sig-
iﬁcantly better in group B than in group A. The 5-
nd 10-year event-free survival rates for all-cause
ortality were 56.4% and 16.5% [95%CI: 4.7—9.5] in
roup A versus 67.5% and 52.7% [95%CI: 8.1—12.0]
log-rank test, p = 0.043) in group B. The 5- and
0-year event-free survival rates for cardiac death
ere 75.4% and 22.0% [95%CI: 6.1—11.0] in group
versus 81.2% and 71.3% [95%CI: 10.5—14.1] (log-
ank test, p = 0.014) in group B (Fig. 2).
1989) Group B (1990—2005) p
42
71± 5 0.123
28 (67%) 0.474
30 (71%) 0.184
12 (29%) 0.184
13 (31%) 0.474
12 (29%) 1.000
37 (88%) <0.001
22 (52%) 0.001
1/5 (14%) <0.001
39 (93%) 1.000
30 (71%) 0.254
5 (12%) 0.356
Association; VT, ventricular tachycardia; ACEI, angiotensin-
lockers.
114 T. Kubo et al.
Table 2 Echocardiographic and cardiac catheterization ﬁndings
Group A (1982—1989) Group B (1990—2005) p
Echocardiography (n) 12 42
LV end-diastolic diameter (mm) 7± 5.9 62± 6.6 0.039
LV end-systolic diameter (mm) 58± 5.2 52± 8.1 0.028
Fractional shortening (%) 13± 4.7 16± 5.4 0.071
IVS (mm) 11.0± 1.12 9.9± 1.74 0.072
PW (mm) 11.6± 2.46 9.6± 1.36 0.045
Left atrial diameter (mm) 43± 5.0 42± 7.5 0.784
Cardiac catheterization (n) 9 39
LVEDVI (ml/m2) 151± 20 151± 50 0.972
LVESVI (ml/m2) 112± 21 99± 41 0.203
LVEF (%) 24± 9 35± 10 0.004
LVEDP (mmHg) 12± 5 11± 6 0.438
Ao sys (mmHg) 132± 35 117± 20 0.298
PCWP (mmHg) 11± 5 9± 6 0.629
PA (mean) (mmHg) 22± 9 18± 9 0.221
RVEDP (mmHg) 7± 3 7± 3 0.870
RA (mean) (mmHg) 7± 8 5± 3 0.283
Cardiac index (ml) 2.5± 0.9 2.1± 0.4 0.285
Data shown as mean± S.D. LV, left ventricular; IVS, interventricular septum thickness; PW, posterior wall thickness; LVEDVI, left
end-
pulm
p
d
o
h
p
cventricular end-diastolic volume index; LVESVI, left ventricular
LVEDP, left ventricular end-diastolic pressure; Ao, aorta; PCWP,
right ventricular end-diastolic pressure; RA, right atrium.
Discussion
Dilated cardiomyopathy is a primary myocardial
disease of unknown cause characterized by left
ventricular dilatation and impaired myocardial con-
tractility. Although DCM had a poor prognosis in
the past, there have been several reports of bet-
ter prognosis than that of two decades ago, partly
because of the widespread use of ACEI, ARB and -
blockers in the treatment of heart failure following
t
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Figure 1 Clinical outcomes during follow-up period. DCM=di
Group B: diagnosis in 1990—2005.systolic volume index; LVEF, left ventricular ejection fraction;
onary capillary wedge pressure; PA, pulmonary artery; RVEDP,
ublication of results of several large-scale, ran-
omized clinical studies showing beneﬁcial effects
f thosemedications on the survival of patients with
eart failure. However, because not many elderly
atients are often included in these randomized
linical studies, there is little information about
he improvement of prognosis in elderly patients
ith DCM. The present study showed that the long-
erm prognosis of DCM in the elderly patients had
igniﬁcantly improved over the past 20 years.
lated cardiomyopathy. Group A: diagnosis in 1982—1989.
Improvement in prognosis of dilated cardiomyopathy in
Figure 2 (A) Kaplan—Meier curves for all-cause mortal-
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disease, particularly in the elderly.ty during follow-up. (B) Kaplan—Meier curves for cardiac
eath during follow-up.
aseline characteristics
n the present study, there were no signiﬁcant dif-
erences in age, gender, NYHA functional class,
nd the prevalence of atrial ﬁbrillation and ven-
ricular tachycardia between group A (diagnosis in
982—1989) and group B (diagnosis in 1990—2005).
n the other hand, LV size determined by echocar-
iography and LV systolic function measured by
iplane left ventriculography were signiﬁcantly
ifferent, although other echocardiographic and
ardiac catheterization ﬁndings were not. Taking
ccount of these differences, i.e., larger LV size
nd lower ejection fraction in group A, it is possi-
le that patients in group A might have had slightly
ore advanced DCM in terms of systolic dysfunction
t the time of diagnosis.
Based on growing evidence from large-scale, ran-
omized clinical studies, we intentionally increased
he use of ACEI after 1990 and then -blockers
t our institute. Thus, the frequency of use of
b
g
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CEI/ARB and -blockers was signiﬁcantly higher
n group B than in group A. About 90% of the
atients in group B received ACEI and/or ARB.
hese medications were used with the expectation
f favorable prognostic effects, including preven-
ion of LV remodeling. Although -blockers were
ore frequently prescribed in group B than in group
, only half of the patients in group B received
-blockers in this study, because our institute com-
enced -blocker therapy for the management of
eart failure from the latter half of the 1990s.
ndeed, 83% of the patients in group B had -blocker
herapy after 1996. On the other hand, class Ia or Ib
ntiarrhythmics were less frequently used in group
than in group A. This declined use of antiarrhyth-
ics was probably due to the results of the studies
hich have shown adverse effects from antiarrhyth-
ics (class I) on the survival of patients with heart
ailure [20—23].
mproved survival
aplan—Meier analysis showed that survival curves
or all-cause mortality and cardiac death were
igniﬁcantly better in group B than in group A,
lthough it was not a bad survival even in group
(possibility of the reason for the good outcome
n group A was that 10 of the 12 patients in
roup A took spironolactone which was reported
o reduce the risk of both morbidity and mortal-
ty among patients with severe heart failure). [24].
his change in mortality may reﬂect better treat-
ent, but also earlier detection of disease.
The patients in group A had signiﬁcantly larger
V sizes and more impaired LV systolic function than
hose in group B. These results indicate that the
atients in group A might have had more advanced
yocardial damage at the time of diagnosis than
atients in group B. Relatively earlier diagnosis
ight have been made in patients in group B,
lthough NYHA functional class did not differ sig-
iﬁcantly between the two groups. One possible
eason for detection of the disease at an earlier
tage is that echocardiography has come into wide
se. Diagnosis of heart failure is sometimes dif-
cult in the elderly, because symptoms of heart
ailure are often atypical or even absent. Also,
any older patients may not have dyspnea on exer-
ion because of their sedentary lifestyle [25]. The
ecent widespread use of echocardiography in clin-
cal practice may contribute early detection of theThe frequency of use of ACEI/ARB and/or -
lockers was signiﬁcantly higher in group B than in
roup A. These medications were believed to have
avorable prognostic effects based on the results
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of several large-scale, randomized clinical stud-
ies [10—15]. Although not many elderly patients
are included in these randomized clinical stud-
ies, the present study indicates the possibility that
ACEI/ARB and/or -blockers affect long-term sur-
vival in elderly patients with DCM. Furthermore,
the declined use of antiarrhythmics (class I) may
also have an inﬂuence on the better survival.
Clinical implications
Background differences such as medical treatment
and early detection of disease for improvement
in the survival rate of elderly patients with DCM
over the past 20 years give a hint of better man-
agement of the patients. First, both ACEI/ARB and
-blockers should be recommended as standard
therapy even in the elderly patients taking into
consideration that the therapeutic range is nar-
row in treating elderly patients; elderly patients
may have a high risk of adverse effects attributable
to treatment compared with the risk in younger
patients. Furthermore, the ‘‘upstream’’ approach
to antiarrhythmic therapy should be considered ﬁrst
in patients with DCM who have arrhythmias. From
the view point of this antiarrhythmic therapy, the
use of ACEI/ARB and -blockers is very important.
Second, early detection and accurate diagnosis of
the disease are very important. Symptoms of heart
failure are often atypical or even absent in the
elderly [25]. Also, elderly patients with typical
symptoms of heart failure are often misdiagnosed
with other diseases, including chronic pulmonary
disease, anemia, or just generalized weakness asso-
ciated with aging. Proper and early detection of the
disease by echocardiography as well as biomarkers
such as plasma B-type natriuretic peptide is desir-
able.
Limitations
There are several limitations to be acknowledged in
the present study. First, this study was not prospec-
tive and randomized. Second, the number of the
subjects was small and some of the statistical anal-
yses might have been affected. Unfortunately, a
multivariate analysis was not used to evaluate the
prognostic values of these clinical proﬁles because
of the small sample numbers. Further studies on
changes in prognosis using larger numbers of elderly
patients with DCM are needed. Third, although the
use of ACEI/ARB and -blockers seems to have a
favorable effect on the prognosis of elderly patients
with DCM, the appropriate dose of those medica-
tions to have a beneﬁcial effect on prognosis in the
elderly is still not known.
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onclusions
he long-term prognosis of DCM in elderly patients
as signiﬁcantly improved over the past 20 years. A
omparison of the baseline clinical characteristics
f patients in the groups before 1990 and after 1990
ndicates that the advances in the pharmacologic
reatment, the increased use of ACEI/ARB and/or
-blockers and the declined use of antiarrhythmics
class I), and earlier diagnosis may have contributed
o the better survival of elderly patients.
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